AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
IT Tech Packaging, Inc.
Video analysis: ITP
All videosNo video analysis for this stock yet. Request one from our team.
News: ITP
Head-To-Head Review: IT Tech Packaging (NYSE:ITP) & Acadian Timber (OTCMKTS:ACAZF)
Acadian Timber (OTCMKTS:ACAZF - Get Free Report) and IT Tech Packaging (NYSE: ITP - Get Free Report) are both materials companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings. Valuation and Earnings This table compares Acadian
Head to Head Survey: Interfor (OTCMKTS:IFSPF) and IT Tech Packaging (NYSE:ITP)
IT Tech Packaging (NYSE: ITP - Get Free Report) and Interfor (OTCMKTS:IFSPF - Get Free Report) are both materials companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends. Analyst Recommendations This is a summary of current
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic.
